Skip to search formSkip to main contentSkip to account menu

GIMEMA ALL 0394

National Institutes of Health

Related topics

Related topics

4 relations

Broader (4)

Antineoplastic Combined Chemotherapy ProtocolsCytarabineEtoposideIdarubicin

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two…
Bortezomib-melphalan-prednisone (VMP) and continuous lenalidomide-dexamethasone (Rd) represent the standard treatment of… 
2019
2019
Update of the GIMEMA MDS0306 study: Deferasirox for lower risk transfusion‐dependent patients with myelodysplastic syndromes
Most patients affected by Myelodysplastic syndromes (MDS) develop transfusion dependence, which can be correlated with poorer… 
2018
2018
Bortezomib-Thalidomide-Dexamethasone Versus Thalidomide-Dexamethasone before and after Double Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: Final Analysis of Phase 3…
Introduction: The phase 3 GIMEMA-MMY-3006 trial comparing bortezomib-thalidomide-dexamethasone (VTD) versus thalidomide… 
Review
2017
Review
2017
The NLR and LMR ratio in newly diagnosed MM patients treated upfront with novel agents
Multiple myeloma (MM) is the second most frequent hematological neoplasia, characterized by the accumulation of malignant plasma… 
2015
2015
Impact of Complete Response on Survival with Either Autologous Stem Cell Transplantation or Conventional Chemotherapy: Results of a Pooled Analysis of 5 Phase III Trials in Newly Diagnosed Multiple…
Introduction The introduction of novel agents in the treatment of Multiple Myeloma (MM) led to a significant improvement in the… 
2014
2014
Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy
Substantial efficacy has been demonstrated with bortezomib-melphalan-prednisone in phase III studies in transplant-ineligible… 
2014
2014
Chromosome 1 abnormalities in elderly patients with newly diagnosed multiple myeloma treated with novel therapies
Multiple myeloma is a plasma cell disorder characterized by malignant plasma cell infiltration in the bone marrow, serum and/or… 
2014
2014
Chromosome 1 abnormalities in newly diagnosed elderly multiple myeloma patients treated with novel therapies RUNNING HEAD : Chr 1 abnormalities in MM treated with new drugs
Multiple Myeloma is a plasma cell disorder, characterized by malignant plasma cell infiltration in the bone marrow, serum and/or… 
2013
2013
Absolute monocyte count at diagnosis and survival in mantle cell lymphoma
Chaperot, L., Bendriss, N., Manches, O., Gressin, R., Maynadie, M., Trimoreau, F., Orfeuvre, H., Corront, B., Feuillard, J… 
Highly Cited
2005
Highly Cited
2005
GIMEMA-AIEOPAIDA protocol for the treatment of newly diagnosed acute promyelocytic leukemia (APL) in children.
The role of all-trans retinoic acid (ATRA) in pediatric acute promyelocytic leukemia (APL) is the topic of several ongoing… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)